Luisa Allwohn

Luisa Allwohn

Auto-generated profile, based on publicly available information

Luisa Allwohn

Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Radiation Oncology, Berlin, Germany

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2023 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
FEFelix Ehret
Felix Ehret
JWJosy Wolfgang
Josy Wolfgang
LALuisa Allwohn
Luisa Allwohn
JOJulia Onken
Julia Onken
DWDavid Wasilewski
David Wasilewski
DKDavid Kaul
David Kaul
Glioblastomas (GBM) are the most common malignant primary brain tumors in adults and have a dismal prognosis. Patients frequently suffer from local tumor recurrences, with limited therapeutic options. Re-irradiation represents a possible intervention, but given the recent 5th edition of the World Health Organization classification of central nervous system tumors, studies in isocitrate dehydrogenase wild type (IDH-wt) cohorts undergoing a second course of radiotherapy remain limited. Herein, we sought to describe our institutional experience and outcomes after GBM IDH-wt re-irradiation. GBM patients with confirmed IDH-wt status undergoing re-irradiation were included in this single-center, retrospective analysis. A total of 88 patients were analyzed. The median clinical and radiographic follow-up periods were 4.6 months and 4.4 months, respectively. Most patients had a Karnofsky performance status of at least 80% (n = 57). The median biologically effective dose and 2 Gy equivalent dose (EQD2) for re-irradiations, assuming an α/β ratio of 10 Gy for GBM, were 51.4 and 42.8 Gy, respectively. In total, 71 deaths were recorded. The median overall survival (OS) was 8.0 months. Multivariable Cox regression of OS revealed a positive influence of gross total resection vs. biopsy or no resection (hazard ratio: 0.43, p = 0.02). The median progression-free survival (PFS) was 5.9 months. The multivariable Cox regression for PFS did not detect any significant factors. No clear evidence of radiation necrosis was recorded during the available follow-up. However, only a minority (n = 4) of patients underwent surgery after re-irradiation, none showing histopathological proof of radiation necrosis. The prognosis for recurrent IDH-wt GBM after re-irradiation is poor. Patients who are amenable and able to undergo re-resection may have a favorable OS. A second course of radiotherapy with a moderate cumulative EQD2 and small- to medium-sized planning target volumes appeared safe regarding the occurrence of radiation necrosis.

5 April 2023 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
LALuisa Allwohn
Luisa Allwohn
JWJosy Wolfgang
Josy Wolfgang
JOJulia Onken
Julia Onken
DWDavid Wasilewski
David Wasilewski
SRSiyer Roohani
Siyer Roohani
DKDavid Kaul
David Kaul
Oligodendrogliomas (ODG) are rare, diffusely infiltrating brain tumors, defined by their 1p/19q-codeletion and isocitrate dehydrogenase (IDH) mutation. Herein, we analyze the influence of various tumor and patient characteristics on progression-free survival (PFS) and overall survival (OS) in a homogeneous patient cohort. Patients treated for a 1p/19q-codeleted and IDH-mutant ODG were evaluated. The patient and tumor characteristics were analyzed for their influence on PFS and OS. One-hundred-fourteen patients met the inclusion criteria. The median clinical and radiographic follow-up periods were 68.6 and 69.8 months. The median PFS and OS were 66.9 and 236.0 months, respectively. The 2-, 4- and 6-year PFS rates were 89.5%, 76.3%, and 46.0%. The 2-, 4- and 6-year OS rates were 99.0%, 97.9%, and 96.2%. For WHO grade 2 ODG, extent of resection (p = 0.01, hazard ratio (HR) 0.01; p = 0.02, HR 0.02), radiotherapy (p = 0.01, HR < 0.01) and chemotherapy (p = 0.01, HR < 0.01) were associated with a prolonged PFS. For WHO grade 3 ODG, only a combined radiochemotherapy (RCT) lowered the risk of progression in the multivariable analysis (p = 0.02, HR 0.09). Most RCT patients received temozolomide (TMZ) instead of procarbazine, lomustine, and vincristine. Whereas previous studies often comprise tumors with IDH wild type status and without 1p/19q-codeletion, this homogeneous ODG cohort, as defined by the current WHO classification, demonstrated PFS benefits for various therapies, especially concerning RCT. While this is generally in accordance with comparable studies, more prospective work on homogeneous patient cohorts is required to refine treatment guidelines and to determine the role of TMZ in ODG.

21 June 2025 in Radiotherapy and Oncology
Verified
Journal Article
Open access
FEFelix Ehret
Felix Ehret
LMLucas Mose
Lucas Mose
LALuisa Allwohn
Luisa Allwohn
SMStephan Mose
Stephan Mose
SFSusanne Fichte
Susanne Fichte
AGArne Grün
Arne Grün
Brain tumors are the most common solid neoplasms in pediatric patients. However, treatment options remain limited in cases of local recurrence, metastasis, or inoperability. Stereotactic radiosurgery (SRS) offers a potential treatment option in these scenarios. This multicenter study reviews the indications and outcomes of SRS in treating pediatric central nervous system (CNS) lesions. Pediatric patients, <18 years of age at the time of treatment, who underwent SRS for a CNS lesion at four institutions were retrospectively and prospectively analyzed. A total of 84 pediatric patients were treated for 164 benign or malignant CNS lesions between 2005 and 2023. The most common lesions were arteriovenous malformations (28.6 %), schwannoma (26.2 %), ependymoma (14.3 %), and astrocytoma (10.7 %). The primary indications for SRS were the need for salvage treatment (79.2 %) and palliative care (43.2 %). Most treatments (90.9 %) were performed with single-fraction SRS. The median follow-up time was 30.4 months. In patients treated for AVM, the median times to at least partial obliteration and to complete obliteration were 12.0 months and 38.4 months, respectively. The median local control rates for ependymoma and astrocytoma were 35.5 months and 23.9 months, respectively, while the median local control rates for schwannoma and metastases were not reached. The rate of high-grade treatment-associated toxicity was low (3.6 %). SRS in pediatric patients demonstrated a safety and efficacy profile comparable to that of adult patients. SRS should be considered when conventional treatment options are limited and further evaluated as a treatment option for pediatric patients.

7 June 2025 in Radiotherapy and Oncology
Verified
Journal Article
Open access
SHSina Heider
Sina Heider
LALuisa Allwohn
Luisa Allwohn
ARAlexander Rühle
Alexander Rühle
FEFelix Ehret
Felix Ehret
DKDavid Kaul
David Kaul
CSClemens Seidel
Clemens Seidel
Primary central nervous system lymphoma (PCNSL) is a rare but aggressive disease. The application of radiotherapy (RT) as part of treatment usually involved whole-brain radiotherapy (WBRT). Focal radiotherapy (fRT) might be locally active, but comparative outcome data is lacking. Data from a multicenter registry of the German Society of Radiation Oncology's Neuro-Radio-Oncology Working Group (DEGRO AG-NRO) was analyzed. Patients treated for PCNSL between 2007 and 2023 who received RT at any stage of their disease were included. Kaplan-Meier and Cox proportional hazards regression analyses were conducted to compare survival between focal (fRT) and whole-brain radiotherapy (WBRT). Survival data of 151 patients from eight centers were available. The median age at diagnosis was 66.5 years, and the median Eastern Cooperative Oncology Group Performance Status Scale (ECOG PS) was 2. Eighteen percent of patients (n = 27) received primary RT, 33 % (n = 49) consolidation RT, and 49 % (n = 73) RT for recurrent disease. Median overall survival (OS) from diagnosis was 24.1 months (95 % CI: 14.7-33.4), and median survival after RT was 7.2 months (95 % CI: 4.5-10.0). In patients treated with fRT (n = 28) median OS was 67.6 months (95 % CI: 35.7-99.6) compared to 20.1 months after WBRT (n = 123, 95 % CI: 10.5-29.8) (HR = 0.5, p = 0.016). Median survival after RT was also longer with fRT (44.0 months, 95 % CI: 5.9-82.1) than with WBRT (5.8 months, 95 % CI: 3.2-8.4) (HR = 0.5, p = 0.017). In recurrent disease median PFS after use of fRT was 3.8 months, compared to 3.0 months after WBRT (p = 0.164). After fRT, in 16/28 (39 %) patients tumor progression was observed (2/16 in-field, 3/16 out-field, 3/16 mixed, 8/16 unknown). In multivariate Cox-regression analysis, histology other than diffuse large B-cell lymphoma (HR = 0.345, p < 0.01) and fRT (HR = 0.518, p < 0.05) remained independently associated with improved OS. fRT may be a beneficial treatment option for patients with PCNSL and needs to be studied further in prospective clinical trials.

13 November 2026 in Advances in Radiation Oncology
Verified
Journal Article
Open access
LALuisa Allwohn
Luisa Allwohn
SKSophia Kiesl
Sophia Kiesl
SBSophie T. Behzadi
Sophie T. Behzadi
SMSophie Maier
Sophie Maier
SPSophie Pfeiffer
Sophie Pfeiffer
MDMichal Devecka
Michal Devecka